$NAUT SEC Filings

Filed On	Filing
27 Oct 2026	10-Q
18 Sep 2026	EFFECT
18 Sep 2026	424B5
11 Sep 2026	S-3
11 Sep 2026	SCHEDULE 13D/A
11 Sep 2026	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement Nautilus Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows:
28 Aug 2026	SCHEDULE 13D/A
14 Aug 2026	SCHEDULE 13D/A
28 Jul 2026	10-Q
28 Jul 2026	8-K: Results of Operations and Financial Condition
30 Jun 2026	SCHEDULE 13D/A
22 Jun 2026	Form 4: Posard Matthew L., Director Granted 45,000 Stock Option (Right to Buy)
22 Jun 2026	Form 4: Nazem Farzad, Director Granted 45,000 Stock Option (Right to Buy)
22 Jun 2026	Form 4: Akinsanya Karen, Director Granted 45,000 Stock Option (Right to Buy)
22 Jun 2026	Form 4: McIlwain Matthew S, Director Granted 45,000 Stock Option (Right to Buy)
22 Jun 2026	Form 4: Epperly Melissa B,, Director Granted 45,000 Stock Option (Right to Buy)
18 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
04 Jun 2026	SCHEDULE 13D/A
04 Jun 2026	Form 4: Ah Equity Partners Bio II, L.l.c., 10% owner and 5 others Sold 5,000,000 shares ($11.8M)
28 Apr 2026	ARS

Comments